Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arthritis Res Ther. 2010;12(4):138. doi: 10.1186/ar3114. Epub 2010 Aug 26.

A new tool for detection of type I interferon activation in systemic lupus erythematosus.

Abstract

The IFN-I pathway is activated in systemic lupus erythematosus (SLE) and appears to be important in the pathogenesis of the disease. As a result, several clinical trials of anti-IFN monoclonal antibodies, which hold promise to control the disease, have been launched. Additionally, activation of IFN-I might be important in the prognosis and activity assessment of the disease. Therefore, new biomarkers that reflect activity of the IFN-I pathway and are simple to measure, such as the monocyte CD64 receptor, are expected to have a great impact on the management of SLE, if properly validated.

Comment on

PMID:
20815919
[PubMed - indexed for MEDLINE]
PMCID:
PMC2945060
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk